VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog🤝Partner
Illustration for: OpenAI Adds Nubank, BNY CEOs to Board Ahead of Potential IPO
Value Add VC/Pulse/IPO

OpenAI Adds Nubank, BNY CEOs to Board Ahead of Potential IPO

OpenAI appointed Nubank CEO David Vélez and BNY CEO Robin Vince to its board, adding deep public-markets and financial-services experience as the company builds governance infrastructure suited to a future as a public company.

By the Numbers

2 (Vélez, Vince)
New directors
>$850B
OpenAI valuation
June 2026
S-1 filed (confidential)
Nubank (CEO)
Vélez's company
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 21, 2026
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

OpenAI appointed David Vélez, CEO of Nubank -- the largest digital bank in Latin America -- and Robin Vince, CEO of financial services company BNY, as new independent directors to both its nonprofit and for-profit boards

2

The appointments come as OpenAI, valued at more than $850 billion, confidentially filed its IPO prospectus with the SEC in June, though it hasn't disclosed an official listing timeline

3

Adding two sitting CEOs with extensive public-markets and financial-services governance experience is a deliberate signal that OpenAI is building board infrastructure suited to a public company rather than a research lab, ahead of any actual listing date

4

It lands the same week Anthropic's IPO roadshow reaches the investor-meeting stage, keeping both leading AI labs' public-market preparations moving in parallel even as OpenAI's own listing target has reportedly slipped to 2027

TC

The VC Read · Trace's Take

Trace Cohen

Adding a bank CEO and a fintech CEO to your board isn't a research decision, it's a governance decision aimed squarely at public-market investors who'll eventually read OpenAI's proxy statement. The 2027 timeline slip means Anthropic gets to set the comp set first -- but OpenAI clearly isn't treating the delay as a reason to slow down IPO prep, it's using the extra runway to build a cleaner governance story.

Analysis

OpenAI appointed two new independent directors with extensive public-markets experience to its board this week: David Vélez, CEO of Nubank, the largest digital bank in Latin America, and Robin Vince, CEO of financial services giant BNY. Both join OpenAI's nonprofit and for-profit board structures as the company continues preparing for a potential initial public offering.

The appointments arrive as OpenAI -- valued at more than $850 billion in its most recent private round -- works through the aftermath of confidentially filing its IPO prospectus with the SEC in June. The company hasn't disclosed an official listing timeline, and separate reporting has suggested its target has slipped from fall 2026 toward 2027, giving rival Anthropic a real opportunity to reach public markets first among major AI labs.

What makes these specific appointments notable is the kind of experience they bring: Vélez has built and scaled one of the largest publicly traded digital banks in the world, and Vince runs BNY, one of the oldest and most established names in financial services, with deep institutional-investor relationships and public-company governance experience. Adding two sitting CEOs with that specific skill set -- rather than, say, additional AI researchers or technologists -- signals OpenAI is deliberately building the kind of board that satisfies public-market governance expectations well ahead of any actual listing date.

The timing is coordinated with the broader AI-lab IPO race: this appointment lands the same week Anthropic's own IPO roadshow reached the investor-meeting stage, keeping both companies' public-market preparation tracks moving in parallel even as their actual listing timelines diverge, with Anthropic potentially reaching Nasdaq months or over a year ahead of OpenAI.

What to watch: whether OpenAI adds further board members with specific public-company audit, compensation, or risk-committee experience as its own IPO timeline firms up, and whether Vélez or Vince's public commentary on OpenAI's governance offers any signal about how close the company actually is to a 2027 listing versus further delay.

ShareXLinkedInEmail

More on

OpenAI →Nubank →BNY →

Reported by CNBC · Analysis by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Aug 9, 2026

What BofA's Extreme Bull Signal Means for Your Marks

Illustration for: What BofA's Extreme Bull Signal Means for Your Marks
IPO

What BofA's Extreme Bull Signal Means for Your Marks

BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.

IPO· Aug 8, 2026

Biotech IPOs Are Pricing Above Range Again

Illustration for: Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined

Biotech IPOs Are Pricing Above Range Again

BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.

IPO· Aug 7, 2026

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

Illustration for: BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq
IPO$150M IPO

BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq

BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.

@Trace_Cohen·t@nyvp.com